Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy.
Clin Cancer Res. 2024 May 15;30(10):2160-2169. doi: 10.1158/1078-0432.CCR-24-0106.
Clin Cancer Res. 2024.
PMID: 38466643
ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease.
Stecklein SR, Kimler BF, Yoder R, Schwensen K, Staley JM, Khan QJ, O'Dea AP, Nye LE, Elia M, Heldstab J, Home T, Hyter S, Isakova K, Pathak HB, Godwin AK, Sharma P.
Stecklein SR, et al. Among authors: nye le.
NPJ Breast Cancer. 2023 Mar 6;9(1):10. doi: 10.1038/s41523-023-00512-7.
NPJ Breast Cancer. 2023.
PMID: 36878909
Free PMC article.
Item in Clipboard
Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial.
Sharma P, Stecklein SR, Yoder R, Staley JM, Schwensen K, O'Dea A, Nye L, Satelli D, Crane G, Madan R, O'Neil MF, Wagner J, Larson KE, Balanoff C, Kilgore L, Phadnis MA, Godwin AK, Salgado R, Khan QJ, O'Shaughnessy J.
Sharma P, et al.
JAMA Oncol. 2024 Feb 1;10(2):227-235. doi: 10.1001/jamaoncol.2023.5033.
JAMA Oncol. 2024.
PMID: 37991778
Clinical Trial.
Item in Clipboard
Cite
Cite